Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-12-06 4:28 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BlackRock Inc. BLK | 8,787,650 10.300% | 548,570 (+6.66%) | View |
| 2024-11-08 5:31 pm Unchanged | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BlackRock Inc. BLK | 8,239,080 9.700% | 0 (Unchanged) | View |
| 2024-11-08 10:52 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | WELLINGTON MANAGEMENT GROUP LLP | 4,985,976 5.860% | -2,599,245 (-34.27%) | View |
| 2024-10-21 4:11 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BlackRock Inc. BLK | 8,239,080 9.700% | 1,223,532 (+17.44%) | View |
| 2024-10-18 11:49 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | STATE STREET CORP STT | 3,770,826 4.400% | -1,245,398 (-24.83%) | View |
| 2024-02-14 12:50 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Kynam Capital Management LP | 5,660,000 6.670% | 5,660,000 (New Position) | View |
| 2024-02-14 07:01 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Point72 Asset Management L.P. | 2,834,499 3.300% | -685,903 (-19.48%) | View |
| 2024-02-13 9:44 pm Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Avidity Partners Management LP | 3,950,000 4.700% | -2,768,142 (-41.20%) | View |
| 2024-02-13 5:15 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | VANGUARD GROUP INC | 4,335,353 5.110% | 4,335,353 (New Position) | View |
| 2024-02-08 10:18 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | WELLINGTON MANAGEMENT GROUP LLP | 7,585,221 8.940% | -398,221 (-4.99%) | View |
| 2024-01-25 4:59 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BlackRock Inc. BLK | 7,015,548 8.300% | 2,663,516 (+61.20%) | View |
| 2024-01-25 11:20 am Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | STATE STREET CORP STT | 5,016,224 5.910% | 1,367,761 (+37.49%) | View |
| 2023-10-31 4:26 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Point72 Asset Management L.P. | 3,520,402 5.100% | 3,520,402 (New Position) | View |
| 2023-10-05 12:23 pm Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Frazier Life Sciences Public Fund L.P. | 0 0.000% | -3,708,838 (Position Closed) | View |
| 2023-02-14 4:46 pm Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Nantahala Capital Management LLC | 975,705 1.400% | -2,074,854 (-68.02%) | View |
| 2023-02-14 3:47 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Avidity Partners Management LP | 6,718,142 9.700% | 1,474,123 (+28.11%) | View |
| 2023-02-14 12:12 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Frazier Life Sciences Public Fund L.P. | 3,708,838 5.400% | 936,776 (+33.79%) | View |
| 2023-02-14 11:53 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BIOTECHNOLOGY VALUE FUND L P | 1,451,197 2.100% | -3,480,682 (-70.58%) | View |
| 2023-02-06 2:46 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | STATE STREET CORP STT | 3,648,463 5.360% | 3,648,463 (New Position) | View |
| 2023-01-31 5:52 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BlackRock Inc. BLK | 4,352,032 6.400% | 662,138 (+17.94%) | View |